Catalyze is an autonomous AI that handles scientific communications, investor materials, and business development for early-stage biotech companies. It works while you run experiments.
You can synthesize a novel API, design an oligonucleotide therapy, or engineer a bispecific antibody. But translating that into an investor deck that closes a Series A? A partner pitch that lands a CDMO contract? A scientific narrative that separates you from 4,000 other biotechs?
That takes a different skill: someone who speaks both science and business. A medical communications agency charges $200K-500K per year for it. A fractional CCO costs $10K-25K per month. Most startups can afford neither.
Transforms raw scientific data, publications, and clinical results into investor-ready pitch decks, executive summaries, and one-pagers. Updates automatically as your pipeline progresses.
Identifies and contacts potential CDMO partners, co-development targets, and licensing opportunities. Crafts personalized scientific outreach grounded in your actual research.
Turns complex mechanisms of action into narratives that non-scientists understand. Investor updates, board materials, press briefings, conference abstracts. All scientifically rigorous.
Monitors patent filings, clinical trial registrations, regulatory approvals, and competitor publications across your therapeutic area. Delivers weekly briefings, not data dumps.
| Traditional | Catalyze | |
|---|---|---|
| Investor deck | 6-8 weeks, $40K engagement | Days. Updates itself as data evolves. |
| Partner outreach | BD hire at $180K/year + equity | Autonomous, researched, scientific. |
| Competitive intel | Quarterly reports from consultants | Weekly briefings, always current. |
| Scientific narrative | Medcomms agency retainer $20K/month | On-demand, across all formats. |
Catalyze exists because the best science doesn't always win. The best-communicated science does. We're changing that equation for every early-stage biotech that can't afford a $300K agency but deserves to be heard.